MedKoo Cat#: 407179 | Name: IPA-3
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

IPA-3 is a potent and selective PAK1 inhibitor. IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and NF-κB activation. IPA-3 treatment significantly inhibited the growth of HCC cells. The mechanisms through which IPA-3 treatment suppresses HCC cell growth are enhancement of apoptosis and blockage of activation of NF-κB. IPA-3 not only inhibits the HCC cell growth, but also suppresses the metastatic potential of HCC cells. Nude mouse xenograft assay demonstrated that IPA-3 treatment significantly reduced the tumor growth rate and decreased tumor volume, indicating that IPA-3 can suppress the in vivo tumor growth of HCC cells. Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to the high incidences of metastasis and tumor recurrence. Overexpression of p21-activated protein kinase 1 (PAK1) is frequently observed in HCC and is associated with a more aggressive tumor behavior, suggesting that PAK1 is a potential therapeutic target in HCC.

Chemical Structure

IPA-3
IPA-3
CAS#42521-82-4

Theoretical Analysis

MedKoo Cat#: 407179

Name: IPA-3

CAS#: 42521-82-4

Chemical Formula: C20H14O2S2

Exact Mass: 350.0435

Molecular Weight: 350.45

Elemental Analysis: C, 68.55; H, 4.03; O, 9.13; S, 18.30

Price and Availability

Size Price Availability Quantity
10mg USD 285.00 2 Weeks
25mg USD 500.00 2 Weeks
50mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
IPA-3; IPA 3; IPA3.
IUPAC/Chemical Name
1,1'-disulfanediylbis(naphthalen-2-ol)
InChi Key
RFAXLXKIAKIUDT-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H14O2S2/c21-17-11-9-13-5-1-3-7-15(13)19(17)23-24-20-16-8-4-2-6-14(16)10-12-18(20)22/h1-12,21-22H
SMILES Code
OC1=CC=C2C=CC=CC2=C1SSC3=C4C=CC=CC4=CC=C3O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, and shows no inhibition to group II PAKs (PAKs 4-6).
In vitro activity:
IPA‐3 suppressed the proliferation of MEC‐1 in a dose‐dependent manner (Fig. S3A). Of note, IPA‐3 suppressed the viability of ibrutinib‐resistant cells (MEC‐1R) in the same manner (Fig. 6A). Annexin V and PI staining was then performed to investigate whether IPA‐3 triggered cell apoptosis. Incubation of MEC‐1R cells with higher doses of IPA‐3 led to a higher percentage of apoptotic cells, suggesting that cells underwent apoptosis under IPA‐3 treatment (Fig. 6B,C). Reference: Mol Oncol. 2022 Aug;16(16):2920-2935. https://pubmed.ncbi.nlm.nih.gov/35811334/
In vivo activity:
Twice-weekly administration of SSL-IPA3 (5 mg/kg) inhibited the growth of PC-3 tumor xenografts compared with that in the control group (Fig. 1A-C). Reference: Oncol Lett. 2020 Nov;20(5):179. https://pubmed.ncbi.nlm.nih.gov/32934746/
Solvent mg/mL mM
Solubility
DMF 5.0 14.27
DMF:PBS (pH 7.2) (1:4) 0.2 0.57
DMSO 35.7 101.98
Ethanol 7.0 19.97
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 350.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wu Z, Wang L, Fan L, Tang H, Zuo X, Gu D, Lu X, Li Y, Wu J, Qin S, Xia Y, Zhu H, Wang L, Xu W, Li J, Jin H. Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia. Mol Oncol. 2022 Aug;16(16):2920-2935. doi: 10.1002/1878-0261.13281. Epub 2022 Jul 22. PMID: 35811334; PMCID: PMC9394240. 2. Li H, Li T, Zou W, Ni M, Hu Q, Qiu X, Yao Z, Fan J, Li L, Huang Q, Zhou R. IPA-3: An Inhibitor of Diadenylate Cyclase of Streptococcus suis with Potent Antimicrobial Activity. Antibiotics (Basel). 2022 Mar 21;11(3):418. doi: 10.3390/antibiotics11030418. PMID: 35326881; PMCID: PMC8944544. 3. Verma A, Najahi-Missaoui W, Cummings BS, Somanath PR. Sterically stabilized liposomes targeting P21 (RAC1) activated kinase-1 and secreted phospholipase A2 suppress prostate cancer growth and metastasis. Oncol Lett. 2020 Nov;20(5):179. doi: 10.3892/ol.2020.12040. Epub 2020 Aug 31. PMID: 32934746; PMCID: PMC7471734. 4. Møller LLV, Jaurji M, Kjøbsted R, Joseph GA, Madsen AB, Knudsen JR, Lundsgaard AM, Andersen NR, Schjerling P, Jensen TE, Krauss RS, Richter EA, Sylow L. Insulin-stimulated glucose uptake partly relies on p21-activated kinase (PAK)2, but not PAK1, in mouse skeletal muscle. J Physiol. 2020 Dec;598(23):5351-5377. doi: 10.1113/JP280294. Epub 2020 Sep 17. PMID: 32844438; PMCID: PMC7771197.
In vitro protocol:
1. Wu Z, Wang L, Fan L, Tang H, Zuo X, Gu D, Lu X, Li Y, Wu J, Qin S, Xia Y, Zhu H, Wang L, Xu W, Li J, Jin H. Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia. Mol Oncol. 2022 Aug;16(16):2920-2935. doi: 10.1002/1878-0261.13281. Epub 2022 Jul 22. PMID: 35811334; PMCID: PMC9394240. 2. Li H, Li T, Zou W, Ni M, Hu Q, Qiu X, Yao Z, Fan J, Li L, Huang Q, Zhou R. IPA-3: An Inhibitor of Diadenylate Cyclase of Streptococcus suis with Potent Antimicrobial Activity. Antibiotics (Basel). 2022 Mar 21;11(3):418. doi: 10.3390/antibiotics11030418. PMID: 35326881; PMCID: PMC8944544.
In vivo protocol:
1. Verma A, Najahi-Missaoui W, Cummings BS, Somanath PR. Sterically stabilized liposomes targeting P21 (RAC1) activated kinase-1 and secreted phospholipase A2 suppress prostate cancer growth and metastasis. Oncol Lett. 2020 Nov;20(5):179. doi: 10.3892/ol.2020.12040. Epub 2020 Aug 31. PMID: 32934746; PMCID: PMC7471734. 2. Møller LLV, Jaurji M, Kjøbsted R, Joseph GA, Madsen AB, Knudsen JR, Lundsgaard AM, Andersen NR, Schjerling P, Jensen TE, Krauss RS, Richter EA, Sylow L. Insulin-stimulated glucose uptake partly relies on p21-activated kinase (PAK)2, but not PAK1, in mouse skeletal muscle. J Physiol. 2020 Dec;598(23):5351-5377. doi: 10.1113/JP280294. Epub 2020 Sep 17. PMID: 32844438; PMCID: PMC7771197.
1: Ji X, Zhang W, Zhang L, Zhang L, Zhang Y, Tang P. Inhibition of p21-activated kinase 1 by IPA-3 attenuates secondary injury after traumatic brain injury in mice. Brain Res. 2014 Oct 17;1585:13-22. doi: 10.1016/j.brainres.2014.08.026. Epub 2014 Aug 20. PubMed PMID: 25148711. 2: Kuželová K, Grebeňová D, Holoubek A, Röselová P, Obr A. Group I PAK inhibitor IPA-3 induces cell death and affects cell adhesivity to fibronectin in human hematopoietic cells. PLoS One. 2014 Mar 24;9(3):e92560. doi: 10.1371/journal.pone.0092560. eCollection 2014. PubMed PMID: 24664099; PubMed Central PMCID: PMC3963893. 3: Wong LL, Lam IP, Wong TY, Lai WL, Liu HF, Yeung LL, Ching YP. IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and NF-κB activation. PLoS One. 2013 Jul 19;8(7):e68843. doi: 10.1371/journal.pone.0068843. Print 2013. PubMed PMID: 23894351; PubMed Central PMCID: PMC3716906.